Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Aging|March 12, 2020
Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADEEurydice Angeli, Kader Chouahnia, Florence Canoui-Poitrine, et al.
Vaccines|December 8, 2020
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung CancerSanjana Monirul, Marthe Rigal, Kader Chouahnia, et al.
Thoracic Cancer|November 18, 2022
Incidence, management, and outcome of lung cancer in patients with long-term oxygen therapyTimothée Lambert, Kinan El Husseini, Maeva Zysman, et al.
Clinical Nutrition (Edinburgh, Scotland)|December 26, 2018
Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) studyFrederic Pamoukdjian, Thomas Aparicio, Florence Canoui-Poitrine, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 9, 2016
Nuclear magnetic resonance spectroscopic analysis of salivary metabolome in sarcoidosisBoris Duchemann, Mohammed Nawfal Triba, Dominique Guez, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 4, 2014
Laryngeal sarcoidosis: a case-control studyBoris Duchemann, Armelle Lavolé, Jean-Marc Naccache, et al.
Bulletin Du Cancer|December 5, 2014
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]Capucine Baldini, Boris Duchemann, Antoine Hollebecque, et al.
Clinical Lung Cancer|January 30, 2019
Immunotherapy for LELC: Case Report and a Focused ReviewMarie Darrason, Antoine Martin, Michael Soussan, et al.
Chest|July 24, 2021
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICUYacine Tandjaoui-Lambiotte, Yanis Akrour, Aude Gibelin, et al.
JCO Oncology Practice|December 15, 2025
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor AdministrationPasquale F Innominato, Thierry Landré, Abdoulaye Karaboué, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Aging|March 12, 2020
Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADEEurydice Angeli, Kader Chouahnia, Florence Canoui-Poitrine, et al.
Vaccines|December 8, 2020
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung CancerSanjana Monirul, Marthe Rigal, Kader Chouahnia, et al.
Thoracic Cancer|November 18, 2022
Incidence, management, and outcome of lung cancer in patients with long-term oxygen therapyTimothée Lambert, Kinan El Husseini, Maeva Zysman, et al.
Clinical Nutrition (Edinburgh, Scotland)|December 26, 2018
Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) studyFrederic Pamoukdjian, Thomas Aparicio, Florence Canoui-Poitrine, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 9, 2016
Nuclear magnetic resonance spectroscopic analysis of salivary metabolome in sarcoidosisBoris Duchemann, Mohammed Nawfal Triba, Dominique Guez, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 4, 2014
Laryngeal sarcoidosis: a case-control studyBoris Duchemann, Armelle Lavolé, Jean-Marc Naccache, et al.
Bulletin Du Cancer|December 5, 2014
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]Capucine Baldini, Boris Duchemann, Antoine Hollebecque, et al.
Clinical Lung Cancer|January 30, 2019
Immunotherapy for LELC: Case Report and a Focused ReviewMarie Darrason, Antoine Martin, Michael Soussan, et al.
Chest|July 24, 2021
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICUYacine Tandjaoui-Lambiotte, Yanis Akrour, Aude Gibelin, et al.
JCO Oncology Practice|December 15, 2025
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor AdministrationPasquale F Innominato, Thierry Landré, Abdoulaye Karaboué, et al.
Pageof 9